ArticleJournal of Cancer2020

Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC.

Yan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.